Readthrough therapies-strategies to override PTCs and restore full-length protein expression
First-pass extracted concept
readthrough therapies
Candidate: concept label1 source documents6 linked claims
Live refresh every 5sNext refresh in 5s
Evidence Snippets
Supporting Sources
Linked Claims
Nonsense mutations are responsible for about 11% of gene lesions causing human monogenic diseases.
Quoted textsource-backed
Nonsense mutations, responsible for ~11% of gene lesions causing human monogenic diseases
Readthrough therapies have evolved from early aminoglycosides to modern precision tools including suppressor tRNAs, RNA editing, and CRISPR-based platforms.
Quoted textsource-backed
have evolved from early aminoglycosides to modern precision tools including suppressor tRNAs, RNA editing, and CRISPR-based platforms
Nonsense mutations introduce premature termination codons that lead to truncated proteins and nonsense-mediated mRNA decay.
Quoted textsource-backed
introduce premature termination codons (PTCs) that lead to truncated proteins and nonsense-mediated mRNA decay (NMD)
Readthrough therapies override premature termination codons and restore full-length protein expression.
Quoted textsource-backed
Readthrough therapies-strategies to override PTCs and restore full-length protein expression
A synergistic, modality-tailored approach is advocated to transform nonsense suppression from palliative care to durable, precision-based cures for neurological disorders.
Quoted textsource-backed
We advocate that a synergistic, modality-tailored approach will transform nonsense suppression from palliative care to durable, precision-based cures for once-untreatable neurological disorders.
Clinical translation of readthrough therapies remains hampered by inefficient CNS delivery, variable efficacy, and the absence of personalized stratification.
Quoted textsource-backed
Yet clinical translation remains hampered by inefficient CNS delivery, variable efficacy, and the absence of personalized stratification.